Ascendiant Capital Markets Has Lowered Expectations for Alzamend Neuro (NASDAQ:ALZN) Stock Price

Alzamend Neuro (NASDAQ:ALZN) had its price objective dropped by equities research analysts at Ascendiant Capital Markets from $35.00 to $32.00 in a report issued on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

Alzamend Neuro Price Performance

ALZN opened at $1.29 on Monday. Alzamend Neuro has a 1 year low of $1.06 and a 1 year high of $15.06. The company’s 50 day simple moving average is $1.44 and its 200 day simple moving average is $2.60.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.